Fig. 3: Patient-reported outcomes. | Nature Medicine

Fig. 3: Patient-reported outcomes.

From: Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

Fig. 3: Patient-reported outcomes.The alternative text for this image may have been generated using AI.

a, LS mean percent change in WI-NRS (s.e.) from baseline (BL) through week 24. b, LS mean change (s.e.) in DLQI from BL to week 24. c, LS mean change (s.e.) in Skin Pain NRS from BL through week 24 in PRIME and PRIME2. d, LS mean change (s.e.) in HADS from BL through week 24 in PRIME and PRIME2. *P < 0.05, **P < 0.01, ***P < 0.001. Data were presented as mean ± s.e. The imputed complete data were analyzed by fitting an analysis of covariance (ANCOVA) model with the corresponding BL value, intervention group, documented history of atopy (atopic or non-atopic), stable use of TCS/TCI (yes or no), region and BL antidepressant use (yes or no) as covariates. P values at week 24 are multiplicity-controlled except for LS mean change in total HADS in PRIME2. P values for all the other timepoints are non-multiplicity-controlled.

Back to article page